Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab in Adults With Down Syndrome Regression Disorder
NCT07812181Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab in Down syndrome regression disorder (DSRD). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ublituximab
03
Conditions
Down syndrome regression disorder (DSRD)
Beyond the preview
Go deeper on NCT07812181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812181.